Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2015-06-01 Interim / Quarterly Rep…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Immediate Report
Interim / Quarterly Report Classification · 95% confidence The document is a financial update for the first quarter of 2015 from XTL Biopharmaceuticals. It includes detailed financial data such as cash balances, expenses, operating loss, and net loss for the quarter ended March 31, 2015. The presence of consolidated statements of financial position and comprehensive income with specific figures indicates this is a substantive financial report for a quarterly period. The document also discusses operational focus and strategic plans but primarily provides financial results for a quarter, which aligns with the definition of an Interim / Quarterly Report (IR). The document length (7515 characters) and content confirm it is not merely an announcement or a brief summary but a comprehensive quarterly financial report. Therefore, the appropriate classification is IR (Interim / Quarterly Report). Q1 2015
2015-06-01 Hebrew (modern)
Immediate Report
Earnings Release Classification · 98% confidence The document explicitly states, "Attached hereto is a report on *earning release for the quarter ended on March 31, 2015*" and references a PDF file named 'XTL_Bio_Q1_2015_Earnings_Release_isa.pdf'. This structure—a brief filing announcing the availability of a detailed earnings report—fits the definition of an Earnings Release (ER) announcement, which typically contains the key highlights and points to the full document. Although it is short, the content is specifically about the earnings release itself, not just announcing the publication of a report in general (RPA/RNS). Since the content is clearly about quarterly earnings, ER is the most specific fit. Q1 2015
2015-06-01 English
Immediate Report about change of identifying details
Regulatory Filings Classification · 95% confidence The document is an 'Immediate Report about change of identifying details' filed by XTL Biopharmaceuticals Ltd. It explicitly states a change in the corporation's address, telephone number, and fax number, effective 13/05/2015. This type of administrative update regarding contact or identifying details does not fit neatly into the specific financial or corporate action categories like 10-K, ER, DIV, or MANG. Since it is a formal regulatory filing announcing a change in basic corporate information, and it doesn't match any other specific category (like DIRS, DVA, or DLST), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings). The document length is short (1892 chars), but it is reporting an event/change, not announcing the publication of a separate, larger report, so RPA is less suitable than RNS for this type of administrative update.
2015-05-13 English
Report of Periodic or Interim Report
Regulatory Filings
2015-04-28 Hebrew (modern)
Report of Periodic or Interim Report
Report Publication Announcement Classification · 98% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' filed under Regulation 3 of the Securities Regulations for a Foreign Corporation. Crucially, it mentions the attached report is 'FORM 20-F-2014' and provides the filename 'XTL_BIOPHARMACEUTICALS_LTD_20F_2014_isa.pdf'. Form 20-F is the annual report filed by foreign private issuers with the SEC, which aligns closely with the definition of a comprehensive annual report (10-K) for foreign entities, or potentially an Interim Report (IR) if it were a half-year filing, but 20-F is typically annual. Given the options, the closest equivalent to a comprehensive annual report is '10-K'. However, the document is very short (1659 chars) and its primary function seems to be announcing the publication of the actual report (the 20-F PDF), fitting the 'Menu vs Meal' rule. Therefore, it is classified as a Report Publication Announcement (RPA).
2015-04-28 English
Immediate Report
Regulatory Filings
2015-04-28 Hebrew (modern)

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.